Preliminary predictive criteria for COVID-19 cytokine storm
- PMID: 32978237
- DOI: 10.1136/annrheumdis-2020-218323
Preliminary predictive criteria for COVID-19 cytokine storm
Abstract
Objectives: To develop predictive criteria for COVID-19-associated cytokine storm (CS), a severe hyperimmune response that results in organ damage in some patients infected with COVID-19. We hypothesised that criteria for inflammation and cell death would predict this type of CS.
Methods: We analysed 513 hospitalised patients who were positive for COVID-19 reverse transcriptase PCR and for ground-glass opacity by chest high-resolution CT. To achieve an early diagnosis, we analysed the laboratory results of the first 7 days of hospitalisation. We implemented logistic regression and principal component analysis to determine the predictive criteria. We used a 'genetic algorithm' to derive the cut-offs for each laboratory result. We validated the criteria with a second cohort of 258 patients.
Results: We found that the criteria for macrophage activation syndrome, haemophagocytic lymphohistiocytosis and the HScore did not identify the COVID-19 cytokine storm (COVID-CS). We developed new predictive criteria, with sensitivity and specificity of 0.85 and 0.80, respectively, comprising three clusters of laboratory results that involve (1) inflammation, (2) cell death and tissue damage, and (3) prerenal electrolyte imbalance. The criteria identified patients with longer hospitalisation and increased mortality. These results highlight the relevance of hyperinflammation and tissue damage in the COVID-CS.
Conclusions: We propose new early predictive criteria to identify the CS occurring in patients with COVID-19. The criteria can be readily used in clinical practice to determine the need for an early therapeutic regimen, block the hyperimmune response and possibly decrease mortality.
Keywords: antirheumatic agents; cytokines; immune system diseases; inflammation.
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
COVID-19 cytokine storm: what is in a name?Ann Rheum Dis. 2021 Jan;80(1):3-5. doi: 10.1136/annrheumdis-2020-219448. Epub 2020 Nov 17. Ann Rheum Dis. 2021. PMID: 33203641 No abstract available.
-
Response to: 'Correspondence on 'Preliminary predictive criteria for COVID-19 cytokine storm'' by Tampe et al.Ann Rheum Dis. 2023 Mar;82(3):e72. doi: 10.1136/annrheumdis-2020-219720. Epub 2021 Jan 7. Ann Rheum Dis. 2023. PMID: 33414184 No abstract available.
-
Correspondence on 'Preliminary predictive criteria for COVID-19 cytokine storm'.Ann Rheum Dis. 2023 Mar;82(3):e71. doi: 10.1136/annrheumdis-2020-219709. Epub 2021 Jan 7. Ann Rheum Dis. 2023. PMID: 33414185 No abstract available.
Similar articles
-
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.Emerg Microbes Infect. 2021 Dec;10(1):266-276. doi: 10.1080/22221751.2021.1884503. Emerg Microbes Infect. 2021. PMID: 33522893 Free PMC article. Review.
-
Cytokine storm in severe COVID-19 pneumonia.J Med Virol. 2021 Sep;93(9):5474-5480. doi: 10.1002/jmv.27068. Epub 2021 May 15. J Med Virol. 2021. PMID: 33963559 Free PMC article.
-
Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.Front Immunol. 2021 Nov 10;12:745515. doi: 10.3389/fimmu.2021.745515. eCollection 2021. Front Immunol. 2021. PMID: 34858403 Free PMC article.
-
Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.Rheumatol Int. 2021 Jan;41(1):7-18. doi: 10.1007/s00296-020-04636-y. Epub 2020 Jun 25. Rheumatol Int. 2021. PMID: 32588191 Free PMC article. Review.
-
The new criteria for a COVID19 patient for the clinical practice to determine the need for an early therapeutic regimen and to decrease mortality.Pak J Med Sci. 2021 Sep-Oct;37(5):1536-1539. doi: 10.12669/pjms.37.5.3630. Pak J Med Sci. 2021. PMID: 34475944 Free PMC article.
Cited by
-
Acute and Chronic Systemic Inflammation: Features and Differences in the Pathogenesis, and Integral Criteria for Verification and Differentiation.Int J Mol Sci. 2023 Jan 6;24(2):1144. doi: 10.3390/ijms24021144. Int J Mol Sci. 2023. PMID: 36674657 Free PMC article.
-
Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience.J Clin Med. 2023 Mar 22;12(6):2429. doi: 10.3390/jcm12062429. J Clin Med. 2023. PMID: 36983429 Free PMC article.
-
Cytokine Storms in the Course of COVID-19 and Haemophagocytic Lymphohistiocytosis in Pregnant and Postpartum Women.Biomolecules. 2021 Aug 13;11(8):1202. doi: 10.3390/biom11081202. Biomolecules. 2021. PMID: 34439868 Free PMC article. Review.
-
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.Cochrane Database Syst Rev. 2023 Jun 1;6(6):CD013881. doi: 10.1002/14651858.CD013881.pub2. Cochrane Database Syst Rev. 2023. PMID: 37260086 Free PMC article.
-
Can proteomics-based approaches further help COVID-19 prevention and therapy?Expert Rev Proteomics. 2021 Apr;18(4):241-245. doi: 10.1080/14789450.2021.1924684. Epub 2021 May 16. Expert Rev Proteomics. 2021. PMID: 33929923 Free PMC article. No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical